Glenmark claims TRPA1 antagonist is ahead of competition as it moves to Phase II
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals hopes to initiate Phase IIa proof-of-concept studies in Europe by March for its TRPA (transient receptor potential ankyrin) 1 receptor antagonist for painful diabetic peripheral neuropathy, GRC 17536, potentially making the molecule the most advanced in its class.